SMARCB1 and epithelioid sarcoma: In addition to purely genomic alterations, other biomarkers have also emerged as potential therapeutic vulnerabilities, such as the loss of INI1 protein in epithelioid sarcoma, as a result of genetic and epigenetic events, targeted with the epigenetic modulator tazemetostat [40].